News

March 26, 2010 – Nearly 14 percent of Medicare beneficiaries admitted with a primary diagnosis of ST-elevated myocardial infarction (STEMI) undergo multivessel primary percutaneous coronary...

Final five-year results from the ENDEAVOR III trial, comparing the Endeavor Zotarolimus-Eluting Coronary Stent to the Cypher Sirolimus-Eluting Coronary Stent, showed Endeavor had lower long-term...

March 15, 2010 — Results from the PERSEUS clinical program demonstrate positive safety and efficacy outcomes in workhorse lesions for a new platinum chromium stent system.

March 15, 2010 — Investigators reported the long-term follow-up of the largest randomized comparison between the two drug-eluting stents during the American College of Cardiology annual meeting...

March 17, 2010 – New data released at the American College of Cardiology Scientific Session this week showed continued positive clinical results for the Xience V everolimus-eluting coronary stent...

March 8, 2010 – A self-expanding and disconnectable stent today gained CE mark approval in Europe to treat acute coronary syndrome (ACS).

March 8, 2010 – Six-month follow-up data on the Stentys drug-eluting and bare metal stents showed a 4 percent restenosis rate in complex lesions.

March 5, 2010 – Experts will lead an evening symposium during ACC 2010 that will cover the latest clinical and experimental breakthroughs in the percutaneous treatment of coronary artery disease....

February 11, 2010 – Former president Bill Clinton received two coronary stents today after being admitted to the hospital with chest pain.

February 2, 2010 – Data published in EuroIntervention (EuroIntervention, 2010; 5:698-702) demonstrate good safety and efficacy, low target vessel revascularization (TVR) and no late stent...

February 1, 2010 – Three patent disputes between Boston Scientific Corp. and Johnson & Johnson (J&J) were settled today with Boston paying $1.7 billion.

The disputes date back to...

January 25, 2010 – Trials for a stent that attracts endothelial progenitor cells show positive results in patients with bifurcation lesions and those with non-ST-segment elevation acute coronary...

January 8, 2010 – Japanese regulatory officials this week cleared the XIENCE V Everolimus-Eluting Coronary Stent. Abbott said it plans to launch sales in Japan in the coming weeks, immediately...

January 5, 2010 – In vivo and in vitro data released yesterday shows a new bioresorbable stent platform allows for complete endothelialization with little inflammation after one month.

January 4, 2010 – The first patient was enrolled the TAXUS Liberte arm of the Dual Anti-Platelet Therapy (DAPT) Study, evaluating the TAXUS Liberté stent in combination with a dual anti-platelet...

November 17, 2009 – Following positive three-year data from the first 30 patients treated with a fully bioabsorbable drug-eluting coronary stent, Abbott is initiating a large-scale trial with...

November 10, 2009 – Clinically, stent fracture has been reported in 1-2 percent of patients after drug-eluting stent (DES) implantation, but researchers at the CVPath Institute Gaithersburg, Md....

November 3, 2009 – Boston Scientific Corp. yesterday said it received CE Mark for its PROMUS Element Everolimus-Eluting Coronary Stent System.

November 3, 2009 – Abbott yesterday said both the XIENCE PRIME Everolimus-Eluting Coronary Stent System and the XIENCE V Everolimus-Eluting Coronary Stent System have received additional new CE...

October 21, 2009 – Raydiance Corp., developer of the world’s first commercial-grade ultrafast laser, said today it made a major breakthrough in manufacturing a wide variety of bioabsorbable...